Your session is about to expire
← Back to Search
Clazosentan for Brain Aneurysm (REACT Trial)
REACT Trial Summary
This trial will compare the effects of adding clazosentan to normal medical care for preventing complications related to cerebral vasospasm after brain aneurysm surgery.
- Brain Aneurysm
REACT Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowREACT Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 3 trial • 409 Patients • NCT03585270REACT Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Does this research study have an age limit?
"In order to take part in this experiment, potential patients must be aged 18-70. There are 58 other trials for minors and 310 for senior citizens."
Are investigators looking for more participants for this clinical trial?
"This specific study is no longer looking for participants. Although, it's worth noting that there are presently 389 trials actively enrolling patients with hemorrhage and 1 Clazosentan trial searching for candidates."
In how many different medical clinics is this medical study being run today?
"To limit participant burden, it is ideal to select a clinical trial site location that is nearest to you. There are 17 sites running this study currently, located in cities such as Saskatoon, New york and Columbus among other places."
What sort of risks are associated with Clazosentan?
"Clazosentan is estimated to be a safe medication, as it has undergone multiple rounds of testing with positive results."
How do I know if I am able to join this particular research study?
"This clinical trial is accepting 409 participants with hemorrhage aged 18 and 70. Most notable, candidates should meet the following criteria: The recruitment into the early treatment group, i.e. subjects without a thick and diffuse clot on the hospital admission CT scan who develop asymptomatic or minimally symptomatic moderate to severe angiographic vasospasm, within the 14-day period post-aneurysm rupture, and for whom it is possible to start study drug in the ICU (or equivalent environment where all protocol assessments can be performed and the Patient Management Guidelines followed), within 24 hours of this angiographic diagnosis"
Could you tell me if Clazosentan has been looked into before?
"Currently, 1 clinical trial is still active and researching Clazosentan. This study is in Phase 3 out of a total 4 phases. Most of the research for Clazosentan takes place in Badalona, but there are also 110 other locations running similar trials."
Is this a new or existing study?
"Idorsia Pharmaceuticals Ltd. has been sponsoring research for Clazosentan since 2018, with the first trial involving 409 patients. After Phase 3 approval was received in 2018, there is now a single active study being conducted by Idorsia Pharmaceuticals Ltd.."
How many willing test subjects are being enrolled in this experiment?
"This particular trial is no longer actively recruiting patients. However, when this study was first posted on December 15th 2018, it did continue to recruit until June 16th 2022. There are also other trials happening related to hemorrhage and Clazosentan with 389 and 1 clinical trials respectively."
Share this study with friends
Copy Link
Messenger